Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction

Phase 4 Completed 79 enrolled University of Zurich Novartis Pharmaceuticals · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate whether valsartan/sacubitril leads to a superior improvement in endothelial function and endocrine status compared to valsartan alone.

Timeline

Start: 2017-05-04
Primary completion: 2020-09-05
Completion: 2020-09-05

Outcome

Missed primary endpoint

paper The primary outcome FMD did not significantly differ between sacubitril/valsartan and valsartan alone PMID 39606217 ↗

Publications

Nagele MP, Haider T, Kreysing L, Barthelmes J, Nebunu D, Rossi VA, Hebeisen M, Sudano I, Ruschitzka F, Flammer AJ. Vascular Endothelial Effects of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction: Randomized Controlled Trial. JACC Adv. 2024 Nov 13;3(12):101392. doi: 10.1016/j.jacadv.2024.101392. eCollection 2024 Dec.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sacubitril	Small molecule	—	Oral
Comparator	Valsartan	Unknown	160 mg	Oral